Hepatic steatosis selectively alters the metabolism of carbamazepine and levetiracetam in vitro without enhancing short-term cellular toxicity. These findings raise concerns about possible modifications in drug exposure, efficacy and tolerability in patients with MASLD, and underscore the need for further in vivo and clinical studies.
Plissonneau et al. (Fri,) studied this question.